These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 8387790

  • 1. In vitro synergistic activity between ofloxacin and ansamycins against Mycobacterium leprae.
    Dhople AM, Ibanez MA, Gardner GD.
    Arzneimittelforschung; 1993 Mar; 43(3):384-6. PubMed ID: 8387790
    [Abstract] [Full Text] [Related]

  • 2. In vitro activity of a new rifamycin derivative against Mycobacterium leprae.
    Dhople AM, Dimova V.
    Arzneimittelforschung; 1996 Feb; 46(2):210-2. PubMed ID: 8720317
    [Abstract] [Full Text] [Related]

  • 3. In vivo susceptibility of Mycobacterium leprae to ofloxacin either singly or in combination with rifampicin and rifabutin. Anti-leprosy activity of ofloxacin and ansamycins in mice.
    Dhople AM, Ibanez MA.
    Arzneimittelforschung; 1994 Apr; 44(4):563-5. PubMed ID: 8011013
    [Abstract] [Full Text] [Related]

  • 4. In-vitro activity of sitafloxacin (DU-6859a), either singly or in combination with rifampin analogs, against Mycobacterium leprae.
    Dhople AM, Namba K.
    J Infect Chemother; 2003 Mar; 9(1):12-5. PubMed ID: 12673400
    [Abstract] [Full Text] [Related]

  • 5. The activity of rifabutin against Mycobacterium leprae.
    Yoder LJ, Jacobson RR, Hastings RC.
    Lepr Rev; 1991 Sep; 62(3):280-7. PubMed ID: 1665534
    [Abstract] [Full Text] [Related]

  • 6. The in-vitro activities of novel benzoxazinorifamycins against Mycobacterium leprae.
    Dhople AM, Ibanez MA.
    J Antimicrob Chemother; 1995 Apr; 35(4):463-71. PubMed ID: 7628981
    [Abstract] [Full Text] [Related]

  • 7. In vitro and in vivo interactions of drugs used in multidrug therapy in leprosy.
    Dhople AM, Lamoureux LC, Gardner GD.
    Indian J Lepr; 1991 Apr; 63(2):166-79. PubMed ID: 1664440
    [Abstract] [Full Text] [Related]

  • 8. Comparative in vitro activities of rifamycin analogues against Mycobacterium leprae.
    Dhople AM.
    Indian J Lepr; 1997 Apr; 69(4):377-84. PubMed ID: 9474513
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. In-vitro activity of three new fluoroquinolones and synergy with ansamycins against Mycobacterium leprae.
    Dhople AM, Ibanez MA.
    J Antimicrob Chemother; 1993 Sep; 32(3):445-51. PubMed ID: 8262866
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. In vitro antimycobacterial activity of newly synthesised S-alkylisothiosemicarbazone derivatives and synergistic interactions in combination with rifamycins against Mycobacterium avium.
    De Logu A, Saddi M, Onnis V, Sanna C, Congiu C, Borgna R, Cocco MT.
    Int J Antimicrob Agents; 2005 Jul; 26(1):28-32. PubMed ID: 15955675
    [Abstract] [Full Text] [Related]

  • 13. In vivo susceptibility of Mycobacterium leprae to sitafloxacin (DU-6859a), either singly or in combination with rifampicin analogues.
    Dhople AM, Namba K.
    Int J Antimicrob Agents; 2003 Mar; 21(3):251-5. PubMed ID: 12636987
    [Abstract] [Full Text] [Related]

  • 14. [Activity of the ansamycins LM 427 and FCE 22250 on atypical mycobacteria in vitro].
    Ungheri D, Morvillo E, Sanfilippo A.
    G Ital Chemioter; 1983 Mar; 30(2-3):97-100. PubMed ID: 6329872
    [No Abstract] [Full Text] [Related]

  • 15. The activity of rifabutin against Mycobacterium leprae in armadillos.
    Dhople AM, Williams SL.
    Int J Antimicrob Agents; 1997 Jan; 9(3):169-73. PubMed ID: 9552713
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The activity of several newer antimicrobials against logarithmically multiplying M. leprae in mice.
    Burgos J, de la Cruz E, Paredes R, Andaya CR, Gelber RH.
    Lepr Rev; 2011 Sep; 82(3):253-8. PubMed ID: 22125933
    [Abstract] [Full Text] [Related]

  • 18. In vitro and in vivo activity of K-130, a dihydrofolate reductase inhibitor, against Mycobacterium leprae.
    Dhople AM.
    Arzneimittelforschung; 1999 Mar; 49(3):267-71. PubMed ID: 10219472
    [Abstract] [Full Text] [Related]

  • 19. Antimycobacterial activities of two newer ansamycins, R-76-1 and DL 473.
    Ji BH, Chen JK, Lu XZ, Wang SY, Ni GX, Hou YH, Zhou DH, Tang QK.
    Int J Lepr Other Mycobact Dis; 1986 Dec; 54(4):563-77. PubMed ID: 3546547
    [Abstract] [Full Text] [Related]

  • 20. Activity of KRM 1648 or rifabutin alone or in combination with clarithromycin against Mycobacterium avium complex in human alveolar macrophages.
    Suzuki K, Tsuyuguchi K, Matsumoto H, Yamamoto T, Hashimoto T, Tanaka E, Amitani R, Kuze F.
    Int J Tuberc Lung Dis; 1997 Oct; 1(5):460-7. PubMed ID: 9441102
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.